Subcutaneous treatments with MVA-MUC1-IL-2 were well tolerated in patients with advanced RCC, prostate cancer, or NSCLC and were shown to induce MUC1 specific responses in some of the patients [34–39]. The gene discussed is MUC1; the disease is prostate carcinoma.